138 related articles for article (PubMed ID: 7736516)
1. Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine.
Abraham R; Aman N; von Borstel R; Darsley M; Kamireddy B; Kenten J; Morris G; Titmas R
Cell Biophys; 1994; 24-25():127-33. PubMed ID: 7736516
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.
Haisma HJ; Van Muijen M; Scheffer G; Scheper RJ; Pinedo HM; Boven E
Hybridoma; 1995 Aug; 14(4):377-82. PubMed ID: 8522350
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
[TBL] [Abstract][Full Text] [Related]
5. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
6. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
[TBL] [Abstract][Full Text] [Related]
7. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
[TBL] [Abstract][Full Text] [Related]
8. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.
Fang L; Battisti RF; Cheng H; Reigan P; Xin Y; Shen J; Ross D; Chan KK; Martin EW; Wang PG; Sun D
J Med Chem; 2006 Oct; 49(21):6290-7. PubMed ID: 17034135
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
[TBL] [Abstract][Full Text] [Related]
10. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
Wallace PM; Senter PD
Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.
Brusa P; Dosio F; Coppo S; Pacchioni D; Arpicco S; Crosasso P; Cattel L
Farmaco; 1997 Feb; 52(2):71-81. PubMed ID: 9181686
[TBL] [Abstract][Full Text] [Related]
12. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Springer CJ; Poon GK; Sharma SK; Bagshawe KD
Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
[TBL] [Abstract][Full Text] [Related]
13. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
14. Sandwich enzyme immunoassay of tumor-associated antigen sialosylated Lewisx using beta-D-galactosidase coupled to a monoclonal antibody of IgM isotype.
Fujiwara K; Matsumoto N; Yagisawa S; Tanimori H; Kitagawa T; Hirota M; Hiratani K; Fukushima K; Tomonaga A; Hara K
J Immunol Methods; 1988 Aug; 112(1):77-83. PubMed ID: 2900265
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.
Vrudhula VM; Svensson HP; Kennedy KA; Senter PD; Wallace PM
Bioconjug Chem; 1993; 4(5):334-40. PubMed ID: 8274516
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of monoclonal antibody-beta-lactamase conjugates in combination with a nitrogen mustard anticancer prodrug in models of human renal cell carcinoma.
Svensson HP; Frank IS; Berry KK; Senter PD
J Med Chem; 1998 Apr; 41(9):1507-12. PubMed ID: 9554883
[TBL] [Abstract][Full Text] [Related]
17. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
Fang L; Sun D
Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
[TBL] [Abstract][Full Text] [Related]
18. Antibody-enzyme conjugates for cancer therapy.
Melton RG; Sherwood RF
J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
[TBL] [Abstract][Full Text] [Related]
19. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
20. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
Sharma SK; Bagshawe KD; Burke PJ; Boden JA; Rogers GT; Springer CJ; Melton RG; Sherwood RF
Cancer; 1994 Feb; 73(3 Suppl):1114-20. PubMed ID: 8306255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
